Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...
Bayer eyes launch of menopause relief, heart drugs this year
Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of ...
Pharmabiz4d
BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval
BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...
The Pharma Letter8d
BridgeBio’s Beyonttra approved in Japan
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...
Dexerto11d
Legendary Japanese dev says “normal people” don’t care about Assassin’s Creed Shadows controversy
Bayonetta creator Hideki Kamiya has defended Assassin’s Creed Shadows believing the game has received a lot of hate from a ...
Sportskeeda7d
Bayonetta director Hideki Kamiya seemingly defends Assassin's Creed Shadows online
Ex-Platinum Games employee Hideki Kamiya has seemingly joined the debate surrounding Assassin's Creed Shadows.
Push Square9d
Assassin's Creed Shadows Gets Positive Reviews In Japan as Bayonetta Director Speaks Out
So, in summary, Japanese reviewers haven't quite put Assassin's Creed Shadows on the same pedestal as Ghost of Tsushima — ...
Business Insider9d
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ...